These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17687345)

  • 21. Clinical cancer research 2001: new agents and therapies.
    Verweij J; de Vries EG
    Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical approval success rates for investigational cancer drugs.
    DiMasi JA; Reichert JM; Feldman L; Malins A
    Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic cancer vaccines on trial.
    Reichert JM; Paquette C
    Nat Biotechnol; 2002 Jul; 20(7):659-63. PubMed ID: 12089545
    [No Abstract]   [Full Text] [Related]  

  • 26. Recombinant protein therapeutics--success rates, market trends and values to 2010.
    Pavlou AK; Reichert JM
    Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
    [No Abstract]   [Full Text] [Related]  

  • 27. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 28. Market watch: upcoming market catalysts in Q3 2012.
    Jeng R
    Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
    [No Abstract]   [Full Text] [Related]  

  • 29. [Participation in the international multi-countries study-operational issues from company view point].
    Hada S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):324-7. PubMed ID: 17301555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke.
    Edwards G
    Drug Discov Today; 2005 Nov; 10(22):1491-4. PubMed ID: 16257369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First Chinese-made biologics slated for human trials in the West.
    Deng B
    Nat Med; 2014 Jun; 20(6):562. PubMed ID: 24901550
    [No Abstract]   [Full Text] [Related]  

  • 32. Discontinued drugs in 2008: cardiovascular drugs.
    Zhang XS; Xiang BR
    Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
    Printz C
    Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hospital network in pediatric oncology].
    Doz F
    Arch Pediatr; 2006 Jun; 13(6):635-7. PubMed ID: 16697587
    [No Abstract]   [Full Text] [Related]  

  • 35. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
    Kelloff GJ; Bast RC; Coffey DS; D'Amico AV; Kerbel RS; Park JW; Ruddon RW; Rustin GJ; Schilsky RL; Sigman CC; Vande Woude GF
    Clin Cancer Res; 2004 Jun; 10(11):3881-4. PubMed ID: 15173097
    [No Abstract]   [Full Text] [Related]  

  • 36. The COPD Pipeline XIII.
    Gross NJ
    COPD; 2011 Dec; 8(6):464-5. PubMed ID: 22149408
    [No Abstract]   [Full Text] [Related]  

  • 37. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 38. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 39. Trends in oncology drug innovation in China.
    Li G; Qin Y; Xie C; Wu YL; Chen X
    Nat Rev Drug Discov; 2021 Jan; 20(1):15-16. PubMed ID: 33154536
    [No Abstract]   [Full Text] [Related]  

  • 40. Cross-boundary cancer studies at the University of Tokyo: Opening a path through research to the future of cancer treatment.
    Noda T
    Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i43-47. PubMed ID: 24516212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.